Shrink the patient group, boost the efficacy: Tonix says a retro look shows promise in select PTSD group
A backwards glance at trial data — and a reshuffling of the patients involved — has reverted failure to optimism for Tonix Pharmaceuticals. At least that’s what company execs are rooting for, according to an update they’ve provided today on its PTSD drug Tonmya.
You might remember Tonmya for the recent Phase III trial flop that washed Tonix’s stock into the gutter, sinking the share price nearly 70% over the past four weeks.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
